GlobeNewsWire
20 Aug 2026, 11:30 UTC · 9w ago
Evaxion announces business update and second quarter 2026 financial results
Impact · against what's priced in
Evaxion's valuation is likely to be driven by the upcoming three-year clinical efficacy data for EVX-01 at ESMO in October, which represents a significant near-term catalyst. Additionally, the transition of EVX-04 toward a regulatory filing for clinical testing provides a tangible de-risking event for the pipeline.
- EVAX+0.60
No priced-in read yet
- In context
The upcoming release of three-year clinical efficacy data for EVX-01 at the October ESMO Congress and the plan to submit a regulatory filing for EVX-04 by year-end provide concrete catalysts for valuation growth.
Read from the article alone
